These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 9462563)

  • 21. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center.
    Li ZQ; Cheng TO; Zhang WW; Qiao SB; Zhao LY; Jin YZ; Guan RM; Liu L
    Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Guo H; Wang P; Xing Y; Peng F; Jiang J; Yang B; You B; Qiu Y; Lee JD
    J Electrocardiol; 2007 Oct; 40(4):356.e1-6. PubMed ID: 17316677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Percutaneous transluminal septal myocardial ablation: early results and long-term follow-up].
    Tekieli Ł; Pieniazek P; Podolec P; Tomkiewicz-Pajak L; Płazak W; Musiałek P; Leśniak-Sobelga A; Przewłocki T; Biernacka B; Zmudka K; Tracz W
    Przegl Lek; 2006; 63(8):628-32. PubMed ID: 17441371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes.
    Gross CM; Schulz-Menger J; Krämer J; Siegel I; Pilz B; Waigand J; Friedrich MG; Uhlich F; Dietz R
    J Endovasc Ther; 2004 Dec; 11(6):705-11. PubMed ID: 15615561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre.
    Bhagwandeen R; Woo A; Ross J; Wigle ED; Rakowski H; Kwinter J; Eriksson MJ; Schwartz L
    Can J Cardiol; 2003 Jul; 19(8):912-7. PubMed ID: 12876612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report.
    Seggewiss H; Faber L; Meyners W; Bogunovic N; Odenthal HJ; Gleichmann U
    Cathet Cardiovasc Diagn; 1998 May; 44(1):65-9. PubMed ID: 9600527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007.
    Fernandes VL; Nielsen C; Nagueh SF; Herrin AE; Slifka C; Franklin J; Spencer WH
    JACC Cardiovasc Interv; 2008 Oct; 1(5):561-70. PubMed ID: 19463359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy.
    Airoldi F; Di Mario C; Catanoso A; Dharmadhikari A; Tzifos V; Anzuini A; Carlino M; Briguori C; Montorfano M; Vaghetti M; Tolaro S; Colombo A
    Ital Heart J; 2000 Mar; 1(3):200-6. PubMed ID: 10806987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world clinical outcomes of percutaneous transluminal septal myocardial ablation for patients with drug-refractory hypertrophic obstructive cardiomyopathy: results from a retrospective multicenter registry of non-high-volume centers.
    Nakamura K; Toba T; Otake H; Kakizaki S; Fujimoto D; Takahashi Y; Fukuyama Y; Kawamori H; Tanaka H; Takaya T; Iwasaki M; Kozuki A; Kawai H; Hayashi T; Shite J; Hirata KI
    Heart Vessels; 2022 Nov; 37(11):1937-1946. PubMed ID: 35641828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience.
    Asil S; Kaya B; Canpolat U; Yorgun H; Şahiner L; Çöteli C; Arat A; Aytemir K
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):557-565. PubMed ID: 29205803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.
    Zeng Z; Wang F; Dou X; Zhang S; Pu J
    Int J Cardiol; 2006 Sep; 112(1):80-4. PubMed ID: 16507323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy.
    Pedone C; Vijayakumar M; Ligthart JM; Valgimigli M; Biagini E; De Jong N; Serruys PW; Ten Cate FJ
    Int J Cardiovasc Intervent; 2005; 7(3):134-7. PubMed ID: 16243734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW; Shi HY; Dai JJ; Chen H; Wu WH; Qiu XB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):294-301. PubMed ID: 32370480
    [No Abstract]   [Full Text] [Related]  

  • 35. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
    Krejcí J; Groch L; Meluzín J; Vykypel T; Halámek J; Vitovec J
    Vnitr Lek; 2006 Apr; 52(4):313-20. PubMed ID: 16755987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percutaneous transluminal septal myocardial ablation: past, present, and future.
    Maekawa Y; Takamisawa I; Takano H; Takayama M
    J Cardiol; 2022 Sep; 80(3):211-217. PubMed ID: 34924238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients.
    Knight C; Kurbaan AS; Seggewiss H; Henein M; Gunning M; Harrington D; Fassbender D; Gleichmann U; Sigwart U
    Circulation; 1997 Apr; 95(8):2075-81. PubMed ID: 9133518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation.
    van der Lee C; Scholzel B; ten Berg JM; Geleijnse ML; Idzerda HH; van Domburg RT; Vletter WB; Serruys PW; ten Cate FJ
    Am J Cardiol; 2008 May; 101(9):1315-20. PubMed ID: 18435964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Ziemssen P
    Cardiol Rev; 1999; 7(6):316-23. PubMed ID: 11208243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.
    van der Lee C; ten Cate FJ; Geleijnse ML; Kofflard MJ; Pedone C; van Herwerden LA; Biagini E; Vletter WB; Serruys PW
    Circulation; 2005 Jul; 112(4):482-8. PubMed ID: 16027255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.